Search

Your search keyword '"Ajami, Gholam Hossein"' showing total 16 results
Start Over Author "Ajami, Gholam Hossein"
16 results on '"Ajami, Gholam Hossein"'

4. Remodeling Process in the Right and Left Atria and Ventricles Following Percutaneous Closure of the Atrial Septal Defect in Children and Adolescents: A Mid-term Study

Author

Amoozgar, Hamid, primary, Safniyat, Saeed, additional, Edraki, Mohammad Reza, additional, Mohammadi, Hamid, additional, Mehdizadegan, Nima, additional, Ajami, Gholam Hossein, additional, Dehghani, Reza, additional, Naghshzan, Amir, additional, Bagherian, Neda, additional, and Shabanpuor-Haghighi, Sajad, additional

Published
2021
Full Text
View/download PDF

8. Effect of Celox® Powder on Initial Hemostasis After Cardiac Catheterization in Pediatric Patients with Congenital Heart Disease: A Prospective Study

Author

Amoozgar, Hamid, primary, Abtahi, Saeed, additional, Edraki, Mohammad Reza, additional, Mohammadi, Hamid, additional, Ajami, Gholam Hossein, additional, Mehdizadegan, Nima, additional, Keshavarz, Kambiz, additional, Moradi, Pouria, additional, Shabanpuor-Haghighi, Sajad, additional, and Zafari, Tahmineh, additional

Published
2020
Full Text
View/download PDF

9. Speckle tracking echocardiography before and after Surgical pulmonary valve replacement in Tetralogy of Fallot patients: Can STE elucidate early left ventricular dysfunction?

Author

Ajami, Gholam Hossein, primary, Alwasabi, Fathi, additional, Mehdizadegan, Nima, additional, Edraki, Mohammad Reza, additional, Mohammadi, Hamid, additional, Amirghofran, Ahmad ali, additional, Ghasemzade, Bahram, additional, Keshavarz, Kambiz, additional, Amoozgar, Hamid, additional, Arabi, Hamid, additional, Naghshzan, Amir, additional, Borzouee, Mohammad, additional, and Peiravian, Farah, additional

Published
2020
Full Text
View/download PDF

11. What is the best angiographic view for detection of coronary artery abnormality in Tetralogy of Fallot? A retrospective study

Author

Edraki, Mohammad reza, primary, Dehdab, Reza, additional, Mehdizadegan, Nima, additional, Mohammadi, Hamid, additional, Amoozgar, Hamid, additional, Ajami, Gholam hossein, additional, Borzouee, Mohammad, additional, Keshavarz, Kambiz, additional, Moradi, Poria, additional, Dehghani, Elham, additional, and Bahrami, Reza, additional

Published
2019
Full Text
View/download PDF

16. Efficacy of Carvedilol in Patients with Dilated Cardiomyopathy due to Beta-thalassemia major; a Double-blind Randomized Controlled Trial.

Author

Ajami, Gholam-Hossein, Amoozgar, Hamid, Borzouee, Mohammad, Karimi, Mehran, Piravian, Farah, Ashrafi, Afsaneh, and Kheirandish, Zahra

Subjects
*ADRENERGIC beta blockers, *CLINICAL trials, *COMPUTER software, *ANTIHYPERTENSIVE agents, *IRON, *CARDIOMYOPATHIES, *RESEARCH funding, *STATISTICS, *T-test (Statistics), *THALASSEMIA, *U-statistics, *DATA analysis, *CLASSIFICATION, *DRUG side effects
Abstract

Objective: Dilated cardiomyopathy is the end result of chronic iron overload in patients with beta thalassemia major. The objective of the present study was to evaluate the safety and efficacy of Carvedilol in patients with beta thalassemia major and dilated cardiomyopathy. Methods: during a six-month period, fourteen patients with beta-thalassemia major and heart failure without diabetes mellitus referred to pediatric cardiology clinic enrolled in this double blind, randomly assigned study. All patients were on anti failure therapy with Digoxin, Captopril and Furosemide. Carvedilol was started at a dosage of 3.12 mg bid and for patients who had a systolic blood pressure >100 mmHg, heart rate >60/min and no signs of low cardiac output the dosage was increased every two weeks to a maximum of 25 mg bid. Clinical signs and symptoms, systolic and diastolic echocardiographic indexes and Tissue Doppler Imaging (TDI) data were collected from each patient. Finding: Eight patients received Carvedilol (Group 1) and six received placebo (Group 2). The mean age of patients in Group 1 and 2 were 16±0.7 years and 17±3 years respectively. Only one patient in Group 1 tolerated increasing Carvedilol dosage to more than 6.25 mg bid. Changes in New York Heart Association (NYHA) classification, Ejection fraction, End diastolic dimension changes, TDI systolic(S), early (Ea) and late (Aa) diastolic waves were not statistically significant in these two Groups (P>0.05). Pulse Doppler E/A wave ratio of mitral valve in Group 1 and Group 2 changed from 1.1±0.37 m/s to 1.8±0.40 m/s and from 1.34±0.30 m/s to 2.6±0.23 m/s respectively (P=0.04). Conclusion: Patients with thalassemia and dilated cardiomyopathy have poor tolerance to increasing Carvedilol dosage and develop decreased systolic blood pressure during advancement of the drug dosage. Carvedilol can be effective in prevention of progression of diastolic dysfunction in these patients. [ABSTRACT FROM AUTHOR]

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results